Biosimilars Advisory Service: Physician Perspectives on Biologics in Immunology and Infectious Disease

With biosimilar infliximab approved in Europe and filed for approval in the United States, rheumatologists and gastroenterologists will soon have the opportunity to prescribe biosimilars to their patients. Understanding the perceptions and expectations of these specialists with regard to biosimilars will be paramount to a biosimilar developer looking to market an immune or infectious disease biologic, particularly because these specialists have to consider the chronic status of their patients and that the biosimilar might be licensed for use in their specialty through indication extrapolation. We conducted primary market research with rheumatologists and gastroenterologists in the United States and Europe to understand their perspectives on biosimilars and their expected adoption rates. Based on our extensive market research, this report also provides highly granular, brand and biosimilar market forecasts for the United States, Europe, and Japan.

Login to access report